Edition:
United States

Baxter International Inc (BAX)

BAX on New York Consolidated

46.10USD
25 Jul 2016
Change (% chg)

$-0.22 (-0.47%)
Prev Close
$46.32
Open
$46.39
Day's High
$46.44
Day's Low
$45.87
Volume
2,601,083
Avg. Vol
8,364,472
52-wk High
$47.22
52-wk Low
$32.18

Latest Key Developments (Source: Significant Developments)

EU Medicines Agency recommends approval of two new cancer drugs
Friday, 22 Jul 2016 07:21am EDT 

EU Medicines Agency : EU medicines agency recommendations for july 2016 . Recommends approval of Exelixis Inc’S cabozantinib to treat advanced renal cell carcinoma .Recommends Approval Of Baxter International Inc’S Irinotecan to treat pancreatic cancer.  Full Article

Baxter International sets quarterly dividend of $0.13 per share
Tuesday, 19 Jul 2016 09:00am EDT 

Baxter International Inc :Sets quarterly dividend of $0.13 per share.  Full Article

Baxter says Delaware court validates amendment to declassify company's board
Thursday, 23 Jun 2016 05:21pm EDT 

Baxter International Inc : Court of Chancery of State of Delaware validated charter amendment to declassify company's board of directors .Charter amendment will become effective on august 1, 2016.  Full Article

Baxter expects to generate free cash flow of about $1.75 bln in 2020
Monday, 9 May 2016 04:05pm EDT 

Baxter International Inc : Company provides financial outlook for 2018 and 2020 . Expects to grow sales 3 to 4 percent on a compounded annual basis at constant currency rates from 2016 through 2018 . Expects a 2018 adjusted operating margin of 14 to 15 percent and 2018 adjusted diluted earnings of $2.10 to $2.25 per share . Also expects free cash flow (operating cash flow less capital expenditures) of approximately $1.0 billion in 2018 . Expects sales to grow approximately 4 percent on a compounded annual basis at constant currency rates from 2016 to 2020 . Anticipates an adjusted operating margin of 17 to 18 percent and adjusted diluted earnings of $2.75 to $3.00 per share in 2020 .Expects to generate free cash flow of approximately $1.75 billion in 2020.  Full Article

Baxter International Inc raises quarterly dividend
Tuesday, 3 May 2016 08:30am EDT 

Baxter International Inc:Board of Directors has declared a 13 percent increase in the company's quarterly dividend rate, from the previous rate of $0.115 per Baxter common share to $0.13 per share.Dividend is payable on July 1, 2016 to stockholders of record as of June 3, 2016.  Full Article

Baxter International Inc raises FY 2016 outlook; gives Q2 2016 outlook
Tuesday, 26 Apr 2016 07:00am EDT 

Baxter International Inc:Says that based on the company's strong first quarter performance, Baxter is raising its financial outlook for FY 2016.Expects constant currency sales growth for FY 2016 of about 3 percent, or about 4 percent after adjusting for increased U.S. competition for cyclophosphamide.Says that on a reported basis, including impact of foreign exchange, Baxter now expects sales to increase about 1 percent as compared to previous guidance of a decline of about 1 percent.Expects earnings from continuing operations, before special items, of $1.59 to $1.67 per diluted share for FY 2016 as compared to previous guidance of $1.46 to $1.54 per diluted share.Expects Q2 2016 constant currency sales growth of about 4 percent, and on a reported basis, sales growth of about 2 percent.Expects earnings from continuing operations, before special items, of $0.38 to $0.40 per diluted share for Q2 2016.Says earnings guidance for Q2 and FY 2016 excludes about $1.94 and $8.01, respectively, per diluted share of realized gains related to the planned use of the Baxalta retained stake.  Full Article

Baxter declares regular quarterly dividend of $0.115 per common share
Tuesday, 16 Feb 2016 08:25am EST 

Baxter International Inc:Declared a regular quarterly dividend of $0.115 per Baxter common share.  Full Article

Baxter International Inc gives FY, Q1 2016 guidance
Tuesday, 2 Feb 2016 07:00am EST 

Baxter International Inc:Expects FY 2016 sales to increase 2 to 3 percent excluding the impact of foreign exchange, and after adjusting for the impact of both foreign exchange and increased U.S. competition for cyclophosphamide, the company expects full-year sales growth of 3 to 4 percent.Says that on a reported basis, including the impact of foreign exchange, Baxter expects sales to decline about 1 percent.Expects earnings from continuing operations, before special items, of $1.46 to $1.54 per diluted share for FY 2016.Expects Q1 2016 expects sales to grow 3 to 4 percent, on a constant currency basisSays.On reported basis, including impact of foreign exchange, the company expects sales to decline about 2 percent.Expects earnings from continuing operations, before special items, of $0.28 to $0.30 per diluted share for Q1 2016.  Full Article

Baxter International Inc - Baxter Initiates Voluntary Nationwide Recall of Select Lots of IV Solutions Due to the Potential for Leaking Containers and Particulate Matter - ENPNWS
Monday, 25 Jan 2016 07:15am EST 

Baxter International Inc:Baxter International Inc. announced today it is voluntarily recalling four lots of intravenous (IV) solutions to the hospital/user level due to the potential for leaking containers and particulate matter. - ENPNWS.Baxter was made aware of these issues as the result of two complaints for leaking containers and one customer complaint each for three lots due to particulate matter. - ENPNWS.In each case, the issue was discovered prior to patient administration and there have been no adverse events associated with these incidents reported to Baxter to date. - ENPNWS.Leaking containers could result in contamination of the solution. If not detected, this could lead to a bloodstream infection, worsened patient condition or other serious adverse health consequences. - ENPNWS.Injecting a product containing particulate matter, in the absence of in-line filtration, may result in blockage of blood vessels, which can result in stroke, heart attack, damage to other organs such as the kidney or liver, or death. - ENPNWS.There is also the possibility of allergic reactions, local irritation and inflammation in tissues and organs. - ENPNWS.  Full Article

Baxter International Inc - Recalls continue to dog Baxter - CHITRI
Thursday, 7 Jan 2016 06:16am EST 

Baxter International Inc:Baxter International, the Deerfield-based maker of hospital and renal products, continued to be dogged with product-quality issues in 2015 as it issued at least five recalls on products from IV solutions to vascular patches - RTRS.Contaminated hospital supplies can be life-threatening, resulting in strokes, heart attacks and organ damage. - RTRS.A string of recalls could raise questions about a supplier's manufacturing and quality-control safeguards - RTRS.In the wake of the recalls, a new CEO, Jose Almeida, took the helm at Baxter this week, with a mission to rebuild the 84-year-old company. - RTRS.Baxter is dealing with the challenge of mature product lines and a slow-growing revenue base after the spinoff last summer of its pharmaceutical operations into the newly formed Baxalta Inc - RTRS.For Baxter, recalls are an ongoing issue. - RTRS.The Food and Drug Administration website shows numerous recalls each year for the past several years, with some that cost the company millions of dollars. - RTRS.  Full Article

BRIEF-Baxter International sets quarterly dividend of $0.13 per share

* Sets quarterly dividend of $0.13 per share Source text for Eikon: Further company coverage: